Evidence map›Paper›PMID 27457813›Full record

ArticleMolecular psychiatry2017

Functional analysis of rare variants found in schizophrenia implicates a critical role for GIT1-PAK3 signaling in neuroplasticity.

M J Kim, J Biag, D M Fass, M C Lewis, Q Zhang, M Fleishman, S P Gangwar, M Machius, M Fromer, S M Purcell and 5 more

Open access · greenAbstract read
In one paragraph

Article in Molecular psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Investigation ofNagoya journal of medical science · 2022
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

M J KimStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
J BiagStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-0891-9567
D M FassStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
M C LewisStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Q ZhangMcGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.
M FleishmanStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
S P GangwarDepartment of Pharmacology and Toxicology, Sealy Center for Structural Biology and Biophysics, University of Texas Medical Branch, Galveston TX, USA.
M MachiusDepartment of Pharmacology and Toxicology, Sealy Center for Structural Biology and Biophysics, University of Texas Medical Branch, Galveston TX, USA.
M FromerStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
S M PurcellStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
S A McCarrollStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
G RudenkoDepartment of Pharmacology and Toxicology, Sealy Center for Structural Biology and Biophysics, University of Texas Medical Branch, Galveston TX, USA.
R T PremontDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
E M ScolnickStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
S J HaggartyStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Broad Institute · USThe University of Texas Medical Branch at Galveston · USDuke Medical Center · USMcGovern Institute for Brain Research · US

Funding

Synaptic Organizers: Dynamic Regulation of Trans-synaptic BridgesR01MH077303 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Gabrielle Rudenko · 2006 to 2026
$8.2M
Functional Genomics of Neuroplasticity in SchizophreniaR01MH095088 · NIMH · BROAD INSTITUTE, INC. · PI HAGGARTY, STEPHEN J · 2011 to 2014
$2.5M
NIMH NIH HHS R01 MH077303NIMH NIH HHS R01 MH095088
6 · The paper itself

Abstract

Although the pathogenesis of schizophrenia (SCZ) is proposed to involve alterations of neural circuits via synaptic dysfunction, the underlying molecular mechanisms remain poorly understood. Recent exome sequencing studies of SCZ have uncovered numerous single-nucleotide variants (SNVs); however, the majority of these SNVs have unknown functional consequences, leaving their disease relevance uncertain. Filling this knowledge gap requires systematic application of quantitative and scalable assays to assess known and novel biological functions of genes. Here we demonstrate loss-of-function effects of multiple rare coding SNVs found in SCZ subjects in the GIT1 (G protein-coupled receptor kinase interacting ArfGAP 1) gene using functional cell-based assays involving coexpression of GIT1 and PAK3 (p21 protein (Cdc42/Rac)-activated kinase 3). Most notably, a GIT1-R283W variant reported in four independent SCZ cases was defective in activating PAK3 as well as MAPK (mitogen-activated protein kinase). Similar functional deficits were found for a de novo SCZ variant GIT1-S601N. Additional assays revealed deficits in the capacity of GIT1-R283W to stimulate PAK phosphorylation in cultured hippocampal neurons. In addition, GIT1-R283W showed deficits in the induction of GAD1 (glutamate decarboxylase 1) protein expression. Extending these functional assays to 10 additional rare GIT1 variants revealed the existence of an allelic series with the majority of the SCZ case variants exhibiting loss of function toward MAPK activation in a manner correlated with loss of PAK3 activation. Taken together, we propose that rare variants in GIT1, along with other genetic and environmental factors, cause dysregulation of PAK3 leading to synaptic deficits in SCZ.

Indexed as

Adaptor Proteins, Signal TransducingCell Culture TechniquesCell Cycle ProteinsGenetic VariationGTPase-Activating ProteinsGuanine Nucleotide Exchange FactorsHEK293 CellsHippocampusHumansMitogen-Activated Protein KinasesNeuronal PlasticityNeuronsp21-Activated KinasesPhosphoproteinsPhosphorylationPolymorphism, Single NucleotideAdaptor Proteins, Signal TransducingCell Cycle ProteinsGIT1 protein, humanGTPase-Activating ProteinsGuanine Nucleotide Exchange FactorsMitogen-Activated Protein Kinasesp21-Activated KinasesPhosphoproteinsProtein Serine-Threonine Kinases

Identifiers

PMID27457813
PMCPMC6186433
OpenAlexW2475706121

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.